View Author
stent patient lesion study trial vessel group score death angiographic outcome revascularization month event syntax score follow-up value infarction diameter syntax target disease sxscore table thrombosis stent thrombosis artery percutaneou difference acef score sirolimus-eluting analysis intervention treatment cardiology polymer artery disease stenosi result biolimus-eluting darapladib point characteristic population hospital in-stent tertile leader procedure ͻ0.001 12 months baseline endpoint drug-eluting serruy all-comer restenosi sirolimus-eluting stent angiographic follow-up netherland 9 months randomized biolimus-eluting stent drug-eluting stents signi everolimus-eluting target lesion revascularization number university plaque safety signi ficantly end point lumen diameter end points placebo department sirolimus-eluting stents comparison effect
10 Most Recent Publications
|
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)
(Article)
Stefanini, G.G. Serruys, P.W.J.C. Linke, A. Klauss, V. Wijns, W. Macaya, C. Garot, P. Mario, C. di Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Silber, S. Gobbens, P. Windecker, S. Khattab, A.A. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbæk, H. Boven, A.J. van Hofma, S.H. |
2011-05-31
|
|
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial
(Article)
Garg, S.A. Serruys, P.W.J.C. Linke, A. Klauss, V. Wijns, W. Macaya, C. Garot, P. Mario, C. di Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Silber, S. Remortel, E. van Ronden, J. Windecker, S. Wykrzykowska, J.J. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbæk, H. Boven, A.J. van Hofma, S.H. |
2011-04-01
|
|
Value of age, creatinine, and ejection fraction (acef score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS Trial
(Article)
Wykrzykowska, J.J. Garg, S.A. Klauss, V. Corti, R. Eberli, F.R. Wijns, W. Morice, M-C. Mario, C. di Geuns, R-J.M. van Jùni, P. Windecker, S. Serruys, P.W.J.C. Onuma, Y. Vries, A. de Goedhart, D. Morel, M-A.M. Es, E.-A. van Buszman, P. Linke, A. Ischinger, T. |
2011-02-01
|
|
Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (limus eluted from a durable versus ERodable stent coating) trial
(Article)
Wykrzykowska, J.J. Garg, S.A. Corti, R. Eberli, F.R. Wijns, W. Morice, M-C. Mario, C. di Geuns, R-J.M. van Juni, P. Windecker, S. Serruys, P.W.J.C. Girasis, C. Vries, T. de Morel, M-A.M. Es, G.A. van Buszman, P. Linke, A. Ischinger, T. Klauss, V. |
2010-07-20
|
|
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
(Article)
Serruys, P.W.J.C. Silber, S. Klauss, V. Wijns, W. Macaya Miguel, C.M. Garot, P. DiMario, C. Manoharan, G. Kornowski, R. Ischinger, T. Bartorelli, A. Ronden, J. Garg, S.A. Geuns, R-J.M. van Richardt, G. Buszman, P. Kelbaek, H. Boven, A.J. Hofma, S.H. Linke, A. |
2010-07-01
|
|
The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial)
(Article)
Sarno, G. Garg, S.A. Mario, C. di Geuns, R-J.M. van Eerdmans, P. Garcia-Garcia, H.M. Es, G.A. van Goedhart, D. Vries, A. de Jüni, P. Meier, B. Windecker, S. Onuma, Y. Serruys, P.W.J.C. Buszman, P. Linke, A. Ischinger, T. Klauss, V. Eberli, F.R. Wijns, W. Morice, M-C. |
2010-02-15
|
|
Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. The LEADERS Trial Substudy
(Article)
Wykrzykowska, J.J. Serruys, P.W.J.C. Eberli, F.R. Wijns, W. Morice, M-C. Mario, C. di Geuns, R-J.M. van Jùni, P. Windecker, S. Onuma, Y. Vries, A. de Es, G.A. van Buszman, P. Linke, A. Ischinger, T. Klauss, V. Corti, R. |
2009-09-01
|
|
Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque
(Article)
Serruys, P.W.J.C. Garcia-Garcia, H.M. Birgelen, C. von D'Amico, D. Hutchinson, T. Zambanini, A. Mastik, F. Es, G.A. van Steen, A.F.W. van der Vince, D.G. Ganz, P. Hamm, C.W. Buszman, P. Wijns, W. Zalewski, A. Erne, P. Verheye, S. Aschermann, M. Duckers, H.J. Bleie, O. Dudek, D. Bøtker, H.E. |
2008-09-09
|
|
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
(Article)
Windecker, S. Serruys, P.W.J.C. Corti, R. Wijns, W. Morice, M-C. Mario, C. di Davies, S. Geuns, R-J.M. van Eerdmans, P. Es, G.A. van Meier, B. Jùni, P. Wandel, S. Buszman, P. Trznadel, S. Linke, A. Lenk, K. Ischinger, T. Klauss, V. Eberli, F.R. |
2008-09-01
|
|
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
(Article)
Serruys, P.W.J.C. Ormiston, J.A. Thuesen, L. Zeiher, A.M. Bett, J.H. Suttorp, M.J. Glogar, H.D. Pitney, M. Wilkins, G.T. Whitbourn, R. Veldhof, S. Miquel, K. Sianos, G. Johnson, R. Coleman, L. Virmani, R. Feyter, P.J. de Sousa, J.E. Grube, E. Heijer, P. den Buszman, P. Schomig, A. Marco, J. Polonski, L. |
2004-10-06
|
